title: Malignant melanoma and tumor necrosis factor-α inhibitors: a case report and review of the literature.
authors.affiliation: Department of Dermatology, Barnet and Chase Farm National Health Service Trust Hospitals, Barnet, UK. jack.mann@ekht.nhs.uk
authors.forename: Jack
authors.initials: J
authors.lastname: Mann
authors.forename: Penelope
authors.initials: P
authors.lastname: Thomson
authors.forename: Howard
authors.initials: H
authors.lastname: Stevens
authors.forename: Ioulios
authors.initials: I
authors.lastname: Palamaras
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008545:Melanoma / Q000209:etiology* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000209:etiology* / Q000473:pathology; D025242:Spondylarthropathies / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept